Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Dae San Yoo"'
Publikováno v:
JAAD Case Reports, Vol 6, Iss 2, Pp 83-85 (2020)
Externí odkaz:
https://doaj.org/article/cf4f6a629c284629ada9334d325d6e9a
Publikováno v:
The Journal of Dermatology. 50:705-709
Patients with refractory bullous pemphigoid (BP) achieve remission after rituximab treatment but require high-dose systemic corticosteroids until the remission. The aim of this retrospective study was to examine the clinical efficacy of omalizumab as
Publikováno v:
Annals of Dermatology. 35
Publikováno v:
Annals of Dermatology. 35
Autor:
Sung Bin Cho, Seungju Lee, Dae San Yoo, Song-Ee Kim, Taehee Kim, Christos C. Zouboulis, Sang Eun Lee
Publikováno v:
Dermatologic Therapy.
Background. Although several energy devices targeting sebaceous glands have been developed, an effective and safe therapeutic tool for hyperseborrhea is still needed. Nonthermal atmospheric-pressure plasma (NTAPP) induces microscopic tissue reactions
Autor:
ZHENLONG ZHENG, DAE SAN YOO, SHANSHAN LI, MEILING PEI, SANG GYUN LEE, JI YOUNG KIM, KEE YANG CHUNG, MI RYUNG ROH
Publikováno v:
Anticancer research. 42(9)
The role of cancer-associated fibroblasts (CAFs) in the pathogenesis of Merkel cell carcinoma (MCC) remains unknown. This study aimed to investigate the clinicopathological significance of CAF subpopulations and their association with tumor-infiltrat
Publikováno v:
Annals of Dermatology. 35:79
Although several energy devices targeting sebaceous glands have been developed, an effective and safe therapeutic tool for hyperseborrhea is needed. Non-thermal atmospheric-pressure plasma (NTAPP) induces microscopic tissue reactions in sebaceous gla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3280de47322a522d8f31c60f3a00cc3
https://doi.org/10.21203/rs.3.rs-729953/v1
https://doi.org/10.21203/rs.3.rs-729953/v1
Publikováno v:
Yonsei Medical Journal
Publikováno v:
JAAD Case Reports
JAAD Case Reports, Vol 6, Iss 2, Pp 83-85 (2020)
JAAD Case Reports, Vol 6, Iss 2, Pp 83-85 (2020)
Pemphigus is a potentially fatal autoimmune blistering disease. Rituximab, a monoclonal antibody against CD20, has increasingly been used in pemphigus patients resistant to conventional therapies. Recently, rituximab therapy has been reported as the